ClinicalTrials.gg
RecruitingNCT05522868Updated Nov 20, 2025

SB17170 Phase 1 Clinical Trial in Solid Tumors

A Phase 1 interventional study of SB17170 in Solid Tumor, sponsored by SPARK Biopharma. Recruiting at 3 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-11-20.

Sponsored by SPARK Biopharma · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
19 Years and older
Sex
All
01

Study summary

Phase 1 Open-label, multicenter, dose escalation, dose expansion study

Read the detailed description

This is an open-label, multicenter, Phase 1 clinical trial to evaluate the maximum tolerated dose, safety, pharmacokinetic/pharmacodynamic characteristics and preliminary anti-tumor activity of SB17170 when administered alone(1a) and co-administered with standard of care(1b) to patients with locally advanced or metastatic solid tumors who have failed standard of care.

1 cycle of treatment of this clinical trial is 21 days, and tumors are assessed every 2 cycles.

02

Conditions studied

  • Solid Tumor
03

In context

Lead sponsor

SPARK Biopharma is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A patient with a or cytologically confirmed diagnosis of locally advanced or solid tumors.
  • A person who has failed the known standard of care or has developed resistance to the standard of care and no longer has applicable standard of care
  • A patient with at least one according to the v1.1 criteria.
  • A person with (ECOG) Performance status of 0 or 1.
  • Those with an expected survival period of 3 months or more at the discretion of of the investigator.

Exclusion criteria

Exclusion Criteria:

  • A patient who has received drugs targeting High Mobility Group Box 1 (HMGB1).
  • A patient who has received or is undergoing chemotherapy (including chemotherapy, radiation therapy, immunotherapy, hormone therapy, targeted therapy, biological products, and tumor embolization) within 28 days from the first administration date of the drug.
  • A person who needs to take drugs or is expected to take them during the study period.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Other
    Cohort 1

    SB17170 initial dose: 300 mg/d per day, 3 to 6 subjects per cohort

    Drug: SB17170

  • Other
    Cohort 2

    SB17170 dose: 600 mg/d per day, 3 to 6 subjects per cohort

    Drug: SB17170

  • Other
    Cohort 3

    SB17170 dose: 1000 mg/d per day, 3 to 6 subjects per cohort

    Drug: SB17170

Interventions

  • SB17170 capsules, Oral administration 21days/cycle

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of SB17170

    Evaluate DLT to estimate the maximum tolerated dose (MTD), and determine a recommended Phase 2 dose (RP2D).

    Time frame: At the end of Cycle 1 (each cycle is 21 days)

Secondary outcomes

  1. Pharmacokinetic(Cmax)

    Peak Plasma Concentration

    Time frame: At Day1 and D21 of Cycle 1 (each cycle is 21 days)

  2. Pharmacokinetic(Tmax)

    Time to Peak Plasma Concentration

    Time frame: At Day1 and D21 of Cycle 1 (each cycle is 21 days)

  3. Pharmacokinetic(AUC)

    Area under the plasma concentration versus time curve

    Time frame: At Day1 and D21 of Cycle 1 (each cycle is 21 days)

  4. The anti-tumor activity with RECIST v1.1

    CT/MRI every 6 weeks

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, up to 100weeks

  5. Pharmacodynamics(TIL)

    Tumor infiltrated lymphocyte in Tumor tissue

    Time frame: At Day1 and D22 of Cycle 1 (each cycle is 21 days)

  6. Pharmacodynamics(TAM)

    Tumor Associated Macrophage at Tumor Tissue

    Time frame: At Day1 and D21 of Cycle 1 (each cycle is 21 days)

  7. Pharmacodynamics(T cell activation)

    T cell activation in Blood

    Time frame: At Day1 and D21 of Cycle 1 and D1 of each cycle (each cycle is 21 days)

  8. Pharmacodynamics(PD-L1)

    PD-L1 in Blood and D1 of each cycle

    Time frame: At Day1 and D21 of Cycle 1 and D1 of each cycle (each cycle is 21 days)

  9. Pharmacodynamics(High Mobility Group Box 1 )

    HMGB1 in Blood and Tissue

    Time frame: At Day1 and D21 of Cycle 1 and D1 of each cycle (each cycle is 21 days)

  10. Pharmacodynamics(S100A8)

    S100A8 in Blood

    Time frame: At Day1 and D21 of Cycle 1 t and D1 of each cycle (each cycle is 21 days)

  11. Pharmacodynamics(S100A9)

    S100A9 in Blood

    Time frame: At Day1 and D21 of Cycle 1 and D1 of each cycle(each cycle is 21 days)

  12. Pharmacodynamics(CXCL8)

    CXCL8 in Blood

    Time frame: At Day1 and D21 of Cycle 1 and D1 of each cycle(each cycle is 21 days)

  13. Pharmacodynamics(MDSC)

    Rate of Myeloid-Drived Suppressor Cell in Blood

    Time frame: At Day1 and D21 of Cycle 1 and D1 of each cycle(each cycle is 21 days)

07

Study locations

1 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2022 (actual). Primary completion is estimated for Jun 2027, 56 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2022
First posted
Aug 31, 2022
StartActual
Oct 17, 2022
Primary completionEst.
Jun 30, 2027
CompletionEst.
Dec 30, 2027
Last update
Nov 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05522868
Lead sponsor
SPARK Biopharma
Responsible party
Sponsor
First posted
Aug 31, 2022
Start date
Oct 17, 2022
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Nov 20, 2025

Study contacts

Sun Bin Kang
Contact
sbkang@sparkbio.co.kr
8228879905
Soojin Jun
study director · SPARK Biopharma

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HMGB1 Inhibitor SB17170

Start the discussion